Recorded fact · drug.label_indication
drug.label_indication for capivasertib|prostate-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 8b51d013 resolves to.
The record
| Fact id | 8b51d013975622d64618d090 |
|---|---|
| Entity | drug: capivasertib|prostate-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260612 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) p
Shown with dashes as hyphens. SHA-256 of the exact stored quote: e3bfff1c056e5714cce274a17a721e7fc896de1d8b4120f620611b894dac355c.
The value
{
"ingredient": "Capivasertib",
"conditionId": "prostate-cancer",
"conditionName": "Prostate Cancer",
"matchedAlias": "prostate cancer",
"context": "indication",
"brand": "TRUQAP",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "d698c106-2322-401e-b738-cbd83c843ecf",
"labelEffectiveTime": "20260612",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: ce77c045d1333099bf9057ebc5e1384551fdddd1c691c9aaf8deb278e5360b01.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.